A research collaboration between scientists at Duke University and the University of North Carolina at Chapel Hill has identified and tested an antibody that limits the severity of infections from a variety of coronaviruses, including those that cause COVID-19 as well as the original SARS illness.
In a virtual media briefing with reporters, Dr. Emmanuel Walter Jr., discussed his study findings, the overall vaccine trial process, potential side effects, and the need for herd immunity in American communities.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $17.5 million over three years to the Duke Human Vaccine Institute to develop a vaccine that protects against multiple types of coronaviruses and viral variants.
Study authors detail measures taken by Duke’s Department of Family Medicine & Community Health (FMCH) that were indicative of the types of responses occurring throughout the country during the COVID-19 pandemic – many of which have staying power
Children and adolescents who had mild to asymptomatic cases of COVID-19 were found to have robust antibody responses up to four months after infection, according to a study of 69 children tested at Duke Health.
The widespread use of masks in schools can effectively prevent COVID-19 transmission and provide a safe learning environment.
If confirmed as a pathogen, the novel canine-like coronavirus could represent the eighth unique coronavirus known to cause disease in humans.
Researchers describe an immune cell found in both monkeys and humans that produces a unique type of anti-glycan antibody that can attach to the outer layer of HIV.
In choosing what to donate, staff took into account surplus items and also the types of items that would be most useful for providing continuous respiratory care.
A potential new vaccine developed by members of the Duke Human Vaccine Institute has proven effective in protecting monkeys and mice from a variety of coronavirus infections.